TIAZAC CAPSULE (EXTENDED RELEASE)

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

DILTIAZEM HYDROCHLORIDE

제공처:

BAUSCH HEALTH, CANADA INC.

ATC 코드:

C08DB01

INN (국제 이름):

DILTIAZEM

복용량:

120MG

약제 형태:

CAPSULE (EXTENDED RELEASE)

구성:

DILTIAZEM HYDROCHLORIDE 120MG

관리 경로:

ORAL

패키지 단위:

15G/50G

처방전 유형:

Prescription

치료 영역:

MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS

제품 요약:

Active ingredient group (AIG) number: 0115863004; AHFS:

승인 상태:

APPROVED

승인 날짜:

2001-11-02

제품 특성 요약

_Product Monograph _
_ _
_ _
_ _
_ _
_Page_
_ 1 of 38 _
_Pr_
_TIAZAC_
_®_
_, Diltiazem Hydrochloride Extended-Release Capsules, USP _
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TIAZAC
®
Diltiazem Hydrochloride,
Extended-Release Capsules 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg,
oral
USP
ANTIHYPERTENSIVE AGENT
ANTIANGINAL AGENT
BAUSCH HEALTH, CANADA INC.
DATE OF INITIAL AUTHORIZATION:
2150 St-Elzear Blvd. West
May 26, 1997
Laval, Quebec
H7L 4A8
DATE OF REVISION:
December 21, 2022
Control #: 266363
_ _
_Product Monograph Page 2 of 38 _
_Pr_
_TIAZAC_
_®_
_,_
_ _
_Diltiazem Hydrochloride Extended-Release Capsules, USP _
RECENT MAJOR LABEL CHANGES
2. CONTRAINDICATIONS
12/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT
LISTED.
TABLE OF CONTENTS
.........................................................................................................
2
PART I: HEALTH PROFESSIONAL
INFORMATION..............................................................
4
1
INDICATIONS.............................................................................................................
4
1.1
Pediatrics
..........................................................................................................
4
1.2
Geriatrics...........................................................................................................
4
2
CONTRAINDICATIONS
..............................................................................................
4
4
DOSAGE AND ADMINISTRATION
.............................................................................
5
4.1
Dosing Considerations
.......................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
................................................... 5
4.4
Administration....................................................................................................
5
4.5
Missed
Dose....................................................